Abstract Body

Aging is the primary risk factor for most chronic diseases of old age, including Alzheimer's disease. Extensive research in biological gerontology has identified shared biological aging processes that go awry with aging and contribute to the development and progression of Alzheimer’s disease. Approximately 75% of ongoing clinical trials in Alzheimer’s are targeting common aging processes, such as senescence, aberrant proteostasis and autophagy, epigenetic dysregulation, mitochondrial oxidative stress, and synaptic dysfunction[KP1] . Each of these mechanisms provides viable therapeutic targets to delay or prevent the onset and progression of Alzheimer’s disease. Further investigation into the synergistic interplay between aging biology and Alzheimer’s disease will reveal new therapeutic avenues, and robust clinical trial designs including a diverse array of validated biomarkers will be critical to advancing this approach. Moreover, as in other chronic age-related diseases, a combination of therapies will likely be needed to fully treat or prevent the disease. Translating the biology of aging into new therapeutics paves the way for a personalized medicine approach to Alzheimer’s, where a combination of therapies can be tailored to individual biomarkers and pathologies.